Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives.

× No keyword cloud information.

6 in total

1. Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline.

Authors: Zhaohui Cai; Anastasia M Christianson; Lars Ståhle; Marianne Keisu
Journal: Eur J Clin Pharmacol Date: 2009-06-25 Impact factor: 2.953

2. Bayesian adaptive designs in single ascending dose trials in healthy volunteers.

Authors: David Guédé; Bruno Reigner; Francois Vandenhende; Mike Derks; Ulrich Beyer; Paul Jordan; Eric Worth; Cheikh Diack; Nicolas Frey; Richard Peck
Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335

Review 3. Generalised anxiety disorder: treatment options.

Authors: John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal: Drugs Date: 2002 Impact factor: 9.546

4. Designing and interpreting the results of first-time-to-man studies.

Authors: A A Patat
Journal: Dialogues Clin Neurosci Date: 2000-09 Impact factor: 5.986

5. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.

Authors: Kari R Nations; Roberta Bursi; Peter Dogterom; Larry Ereshefsky; Lev Gertsik; Tim Mant; Jacques Schipper
Journal: Drugs R D Date: 2012-09-01

6. Design and Conduct Considerations for First-in-Human Trials.

Authors: Jie Shen; Brandon Swift; Richard Mamelok; Samuel Pine; John Sinclair; Mayssa Attar
Journal: Clin Transl Sci Date: 2018-08-24 Impact factor: 4.689

6 in total